Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines is well-positioned to continue its strong financial performance, driven by the success of its flagship drug Brukinsa and its other approved drugs Beqalzi and Tevimbra. The company also has an extensive pipeline of clinical trials, giving it potential for future growth and market share in the oncology therapeutics market. Management's focus on diversity and ethical conduct also bodes well for the company's long-term success.

Bears say

BeOne Medicines is a global oncology company that has a strong focus on developing affordable and accessible oncology medicines. Its flagship product, Brukinsa, has shown promising results in its Phase 3 clinical trial and is on track to generate over $4 billion in global revenues in 2026. The company also has a robust pipeline of over 30 assets in various phases and disease areas, demonstrating their commitment to innovation. However, there is a potential for regulatory and commercial setbacks, emergence of new competitors, and risks to management execution, which could impact the company's overall success.

BeiGene Ltd (ONC) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 12 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Aug 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $398.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $398.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.